MDxHealth's SelectMDx Liquid Biopsy Test for Prostate Cancer

MDxHealth, in conjunction with DDL Diagnostic Laboratory, has launched SelectMDx patient testing in the Netherlands, with plans to expand the offering to other European countries in early 2016. The test is made up of novel biomarkers discovered by Jack Schalakan and uses a non-invasive "liquid biopsy" method to identify patients at low risk for prostate cancer using urine samples. In clinical studies, SelectMDx has been shown to outperform PCA3, improving the information available to urologists seeking to further reduce unnecessary invasive biopsy procedures, said MDxHealth in a statement.